Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004305 · ClinicalTrials.gov registry record
Study of Genetic Anomalies of Complement Related Proteins in Patients With IgA Glomerulonephritis
A clinical trial, sponsored by National Center for Research Resources (NCRR).
- Completed
- Registry status
- 105
- Enrollment target
NCT00004305: Completed study, sponsored by National Center for Research Resources (NCRR).
NCT00004305 is a clinical trial that has completed, run by National Center for Research Resources (NCRR). The registered enrollment target is 105 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004305 has completed, sponsored by National Center for Research Resources (NCRR).
- COMPLETED
- Registry status
- 105 participants
- Enrollment target
Study Summary
OBJECTIVES: I. Determine whether allelic differences associated with the fourth component of complement, type-1 complement receptor expressed on erythrocytes, and Fc receptor FcgRIII contribute to the pathogenesis of IgA glomerulonephritis (IgA-N). II. Compare genetic anomalies of these key components in immune complex processing and clearance between juvenile vs adult onset IgA-N vs normal controls.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 1998-01 |
What the finished NCT00004305 record still lists
NCT00004305 is an observational study that tracks outcomes without assigning an intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00004305 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004305 about?
NCT00004305 is a clinical study titled "Study of Genetic Anomalies of Complement Related Proteins in Patients With IgA Glomerulonephritis". OBJECTIVES: I. Determine whether allelic differences associated with the fourth component of complement, type-1 complement receptor expressed on erythrocytes, and Fc receptor FcgRIII contribute to the pathogenesis of IgA glomerulonephritis (IgA-N). II. Compare genetic anomalies of these key compone...
What is the current status of trial NCT00004305?
This trial is currently completed. The enrollment target is 105 participants. The study started on 1998-01.
Who is sponsoring clinical trial NCT00004305?
This trial is sponsored by National Center for Research Resources (NCRR), which has 94 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03372317 · 105 participants
Tau PET in Imaging and Cognition: Healthy Adults From 55-90
- NCT04253964 · 105 participants · Phase 2
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
- NCT04742452 · 105 participants · NA
Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears
- NCT04875429 · 105 participants · NA
Zenith® Fenestrated+ Clinical Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia